Chemocentryx, Inc.

Zheng Wei

Solomon Ungashe

John Jessen Wright

Andrew Pennell

Thomas J Schall

Zhenhua Miao

Wei Yu Chen

Sreenivas Punna

Yibin Zeng

Andrew M K Pennell

Daniel J Dairaghi

Trevor T Charvat

Jimmie L Moore

Jeff Jin

Derek Hansen

Arindrajit Basak

Brett Anthony Premack

Brett Permack

Qiang Wang

Antoni Krasinski

Maureen Howard

J J Wright

Anita Melikian

Jennifer M Burns

Robert Berahovich

Solomon Ugashe

Anita Melikan

Andrew MK Pennell

M K Andrew Pennell

Arindrajit Badak

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Aryl sulfonamides

Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Bis-aryl sulfonamides

The inventors have discovered that a CK&#x3b2;8-1 truncation variant, CK&#x3b2;8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK&#x3b2;8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK&#x3b2;8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK&#x3b2;8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof

Heteroaryl sulfonamides and CCR2

The present invention is directed to a modified cell migration assay allowing for improved identification and discrimination of chemokine receptor antagonists from non-specific migration blockers.

Method for multiple chemokine receptor screening for antagonists using RAM assay

The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.

Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Growing community of inventors

Redwood City, CA, United States of America

Zheng Wei